A Food and Drug Administration panel is scheduled to vote Thursday on whether to recommend the approval of Pfizer and BioNTech’s coronavirus vaccine for emergency use.
The nonbinding decision from the agency’s Vaccines and Related Biological Products Advisory Committee, an outside group of experts in infectious diseases and vaccines, is the last step before the FDA is likely to give the final OK to distribute the potentially lifesaving doses throughout the United States.
While the FDA does not have to follow the advisory committee’s recommendation, the agency often takes its advice.
